PapersPMID:38068797
The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“No significant difference was seen between the Levagen+ and placebo groups for the allergy symptoms scores (rTNSS) at baseline or throughout the 14 days of treatment.”
- Study
- RCT
- Duration
- 14 days
- Dose studied
- Levagen+ (PEA) 350 mg daily, two 175 mg capsules each morning, against placebo of 175 mg maltodextrin per capsule
- Population
- Adults aged 21 to 77 years with seasonal allergic rhinitis, 108 randomised and 101 completed; whole-population comparison, reflective total nasal symptom score recorded online twice daily
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- otherwise healthy adults aged 18 years or older with seasonal allergic rhinitis
- Participants
- 108
- Comparator
- placebo
- Duration
- 14 days
- Endpoints measured
- 14